T45.1X5D
T45.1X5D — Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
Billable / specific codeICD-10-CMPOA exempt
T45.1X5D is a billable, specific ICD-10-CM code for adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter. It is valid for submission on a claim.
7th character "D" — subsequent encounter
The appropriate 7th character is to be added to each code from category T45
- A
- initial encounter
- D
- subsequent encounter
- S
- sequela
Risk adjustment
T45.1X5D does not map to an HCC and does not risk-adjust under CMS-HCC V28. That is normal — most ICD-10 codes do not. It still needs to be coded correctly; it just will not move a RAF score.
Medicare coverage
T45.1X5D is named in 21 Medicare coverage policies — 21 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A54768Billing and Coding: Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning- MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy
- A56476Billing and Coding: Cardiac Radionuclide Imaging
- A56558Billing and Coding: Allergy Testing
Related codes at this level
Codes that share T45.1X5. If T45.1X5D is not quite right, the correct code is usually one of these.
Questions about T45.1X5D
- Is T45.1X5D a billable ICD-10-CM code?
- Yes. T45.1X5D is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does T45.1X5D sit in the tabular list?
- Injury, poisoning and certain other consequences of external causes (S00-T88), in the block Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances (T36-T50).